Hematological Neoplasms

Chimeric antigen receptor T (CAR-T) cell therapy has shown promising efficacy in early trials for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Priced at $373,000, understanding the cost implications, benefits, and overall impact of Yescarta is crucial for patients and healthcare providers alike.

At the recent 2024 European Hematology Association (EHA) Annual Meeting, the research achievements of Professor Pan Jing’s team from Beijing Gaobeidian Hospital attracted widespread attention.

Kymriah (Tisagenlecleucel) is a CAR-T cell immunotherapy co-developed by the University of Pennsylvania and Novartis, a revolutionary immunocellular therapy.

Serum Eotaxin Predicts Long-Term Survival of Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma Receiving CD19 CAR-T Therapy.

CAR-T cell therapy is an innovative treatment for cancer. The million-dollar CAR-T cell injection has saved the lives of countless patients with difficult-to-treat, relapsed lymphomas, including diffuse large B-cell lymphoma (DLBCL).

Axicabtagene Ciloleucel (axi-cel) Can Provide Durable Remission for Patients with R/R Primary Mediastinal B-Cell Lymphoma (PMBCL).

Recently, the Department of Biological Therapy at the Tumor Medicine Department of the Chinese PLA General Hospital welcomed the return visit of one of the first CAR-T cell therapy patients who received treatment 10 years ago and achieved a cure.

In recent years, CAR-T cell immunotherapy has made breakthrough progress in the field of hematologic malignancies as a revolutionary treatment.

Chimeric antigen receptor (CAR)-modified T cells have successfully treated B cell lymphomas, but applying a similar approach to TCLs is more challenging due to the complexity of targeting T cell antigens.

Recently, a review was published in Molecular Cancer by corresponding authors Prof. Hongbing Zhao from The First Affiliated Hospital of Xinxiang Medical University and Prof. Vivek P. Chavda from Lallubhai Motilal College of Pharmacy (India), and first authors Prof. Zoufang Huang from The First Affiliated Hospital of Gannan Medical University and Prof. Vivek P. Chavda. The review briefly summarized the development of CAR-T cell therapy for MCL. Key points are compiled here for reference.